Bria-PROS+™
Prostate Cancer
Preclinical/Phase 1Planned (1H 2025)
Key Facts
Indication
Prostate Cancer
Phase
Preclinical/Phase 1
Status
Planned (1H 2025)
Company
About BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotech focused on developing targeted cellular immunotherapies to transform cancer care. Its core strategy is advancing Bria-IMT™, a Fast Track-designated candidate in a pivotal Phase 3 study for metastatic breast cancer, while expanding its pipeline through the innovative Bria-OTS™ platform, which enables personalized, off-the-shelf treatments. The company has demonstrated promising clinical data, including extended survival in heavily pre-treated patients, and is backed by collaborations with the National Cancer Institute.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |
| Mitomic™ Test for Prostate Cancer | MDNA Life Sciences | Development/Validation |